The study evaluated whether pre-existing rheumatoid arthritis was associated with a higher mortality and risk for immune-related adverse events with immune checkpoint inhibitor use.
Joining Dr. Ishizawar in conducting this research were UNC colleagues; Dr. Amanda Lusa, Dr. Todd Schwartz, Carolina Alvarez, and Shruti Saxena Beem.
Learn more about the study findings via this summary in Rheumatology Advisor.
Rumey Ishizawar, MD, PhD, is an assistant professor of medicine in the Division of Rheumatology, Allergy and Immunology.